MONROVIA, Calif., March 15, 2017 /PRNewswire/ -- Xencor,
Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical
company developing engineered monoclonal antibodies for the
treatment of autoimmune diseases, asthma and allergic diseases and
cancer, today announced that Bassil
Dahiyat, Ph.D., president and chief executive officer, will
present at the Oppenheimer 27th Annual Healthcare Conference on
Wednesday, March 22, 2017 at
8:35 a.m. ET in New York, NY.
A live webcast of the presentation will be available on the
"Events & Presentations" section in the Investors section of
the Company's website located at
http://investors.xencor.com/events.cfm. A replay of the
presentation will be posted on the Xencor website approximately one
hour after the live event and will be available for 30 days
following the presentation.
About Xencor, Inc.
Xencor is a clinical-stage
biopharmaceutical company developing engineered monoclonal
antibodies for the treatment of autoimmune diseases, asthma and
allergic diseases and cancer. Currently, 11 candidates engineered
with Xencor's XmAb® technology are in clinical development
internally and with partners. Xencor's internal programs include:
XmAb5871 in Phase 2 development for the treatment of IgG4-Related
Disease, and also for the treatment of Systemic Lupus
Erythematosus; XmAb7195 in Phase 1 development for the treatment of
asthma and allergic diseases; XmAb14045 in Phase 1 development for
acute myeloid leukemia; XmAb13676 in Phase 1 development for B-cell
malignancies; and XmAb18087 for the treatment of neuroendocrine
tumors, in pre-clinical development. Xencor's XmAb antibody
engineering technology enables small changes to the structure of
monoclonal antibodies resulting in new mechanisms of therapeutic
action. Xencor partners include Novartis, Amgen, MorphoSys,
Merck, CSL/Janssen, Alexion and Boehringer Ingelheim. For more
information, please visit www.xencor.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/xencor-to-present-at-oppenheimer-27th-annual-healthcare-conference-300421682.html
SOURCE Xencor, Inc.